Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) - February 24-26, 2022 / West Palm Beach, FL
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Comparative Effectiveness of Cladribine Versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MERLYN Study
Brownlee | Poster #095
Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry
Butzkueven | Poster #342
Post-Approval Safety of Cladribine Tablets with Particular Reference to COVID-19 Outcomes: An Update
Giovannoni | Poster #106
Rates of Multiple Sclerosis Relapse, Severe Relapse, and Health Care Resource Utilization Following COVID-19 Vaccination: Real-World Evidence from a US EMR Network
Kuranz | Poster #145
Primary Results from 8-11 Years of Follow-Up in the CLASSIC-MS Study Show Long-Term Efficacy for Patients Who Received Cladribine Tablets in ORACLE MS
Leist | Poster #107
Serum Adipokine Levels in Multiple Sclerosis Patients of the Same Age and Their Association with Clinical and Radiological Measures
Loonstra | Poster #202
A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program
Nicholas | Poster #170
Evobrutinib Promotes Myelin Regeneration in Two Different Models of Demyelination
Zalc | Poster #309
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
Help us direct you to the right information by selecting one of the following options: